InsiderTrades

Form 4 for PMN ProMIS Neurosciences Inc.

Accepted 2024-08-02 00:00:00 ET · period of report 2024-07-31 · accession 0001104659-24-085371 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2024-08-02 2024-07-31 PMN GORDON MICHAEL S 10% P - Purchase — +465.1K 1.58M +42% —
DI 2024-08-02 2024-07-31 PMN GORDON MICHAEL S 10% C - Cnv Deriv — +500.0K 2.08M +32% —
DMI 2024-08-02 2024-07-31 PMN GORDON MICHAEL S 10% P - Purchase — +1.40M 465.1K New —
DI 2024-08-02 2024-07-31 PMN GORDON MICHAEL S 10% C - Cnv Deriv — -500.0K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares, no par value 2024-07-31 P A 465,116 — 1,575,629 I By Title 19 Promis — — (F1) On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
2 Common Common Shares, no par value 2024-07-31 C A 500,000 — 2,075,629 I By Title 19 Promis — — (F3) The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
3 Derivative Tranche A Common Share Purchase Warrants 2024-07-31 P A 465,116 — 465,116 I See footnote — · — to — 465,116 Common Shares (F1) On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. (F5) Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
4 Derivative Tranche B Common Share Purchase Warrants 2024-07-31 P A 465,116 — 465,116 I See footnote — · — to — 465,116 Common Shares (F6) Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. (F1) On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
5 Derivative Tranche C Common Share Purchase Warrants 2024-07-31 P A 465,116 — 465,116 I See footnote — · — to — 465,116 Common Shares (F1) On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. (F7) Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
6 Derivative Series 2 Preferred Shares, no par value 2024-07-31 C D 500,000 — 0 I See footnote — · — to — 500,000 Common Shares (F3) The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. (F2) By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.